In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

To the best of our knowledge, this is the first study to investigate retinal arteriolar hemodynamics and relate the findings to systemic measures of control in a defined cohort of patients at ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

TARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Vabysmo for the treatment of macular edema following retinal vein occlusion. This is the third ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

‒ Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration (AMD) and diabetic macular edema (DME) – ‒ ...

The Global Diabetic Macular Edema Market is experiencing significant growth driven by rising diabetes prevalence and technological advancements in retinal diagnostics like OCT and AI-enabled imaging.

Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...